A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer

Trial Profile

A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Xentuzumab (Primary) ; Everolimus; Exemestane
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Oct 2017 Planned End Date changed from 6 Oct 2017 to 6 Mar 2018.
    • 30 Oct 2017 Planned primary completion date changed from 6 Oct 2017 to 6 Mar 2018.
    • 05 Sep 2017 Planned End Date changed from 9 Aug 2017 to 6 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top